Device for Bacteremia Prevention in Post Cardiac Surgical Intensive Care Unit Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-19

Study Completion Date

2020-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Intravenous catheters are often placed in large (central) veins in critically ill patients to provide special medications or frequent blood sampling. The body reacts to the presence of foreign material by forming a biofilm on the surface within the catheter. Either due to the patients condition or to emergency access to these intravenous lines can become infected with bacteria and reside within the biofilm. When bacteria is grown from these lines it is referred to as: a central line infection. A medical device company (ICU Medical) has obtained the rights to a device that delivers a controlled amount of a cleaning material called chlorhexidine into the catheter to prevent bacterial growth when not in use. Chlorhexidine is the standard cleaning material used on patients when cleaning the skin for surgical procedures or central intravenous catheter insertion. In laboratory tests and animal studies that chlorhexidine inhibits the growth of bacteria and fungi that often cause central line infections. This study will the first assessment in patients with central lines.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Daily Chlorhexidine Bathing and Infection Rates in Critically-ill Patients

NCT02033187

Healthcare Associated Infections

COMPLETED PHASE4

Study of Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit

NCT00549393

Nosocomial Infections

COMPLETED PHASE2/PHASE3

Impact of Daily Bathing With Chlorhexidine in the Critical Patient

NCT02870062

Healthcare Associated Infections

UNKNOWN PHASE1

4% Chlorhexidine Gluconate Daily Bathing for Prevention of Hospital-acquired Infections in Intensive Care Settings

NCT03639363

Hospital Infection

COMPLETED PHASE4

The Effectiveness of Chlorhexidine Gluconate on Prevention of Catheter-Related Bloodstream Infections

NCT05995080

Central Venous Catheter Related Bloodstream Infection Catheter-Related Infections Bloodstream Infection Due to Central Venous Catheter

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Randomization Randomization will be determined using an online random number generator. "www.randomize.net". The research coordinator will randomize the patients and provide bedside staff with the devices when appropriate.

Intervention

Eligible patients that have provided informed consent will be randomized to receive:

1. Steril-flow® (CHG-Lock™) device OR
2. Usual care

Test Protocol

1. For patients randomized to the CHG-LockTM device, attach a attach a BD Posiflush ™ 0.9% Sodium Chloride (Na Cl) 10ml syringe and a CHG-Lock™ device for each IV line that is to be locked. Follow hospital approved protocol for flush, volumes and hand hygiene (see appendix I, II and III).

After a Catheter has been locked, before re-accessing the catheter for further sampling or infusions, all fluid should be aspirated from the catheter to clear the device of CHG, Heparin and the like. This should also confirm patency of the device.
2. Discard the syringe and device in biohazard waste.
3. "Blue Cap" the IV as per routine practice.

* There is no need to use the CHG-Lock™ device for IV lines with IV solutions infusing or those attached to an IV pressure bag, to maintain IV patency.
* If the Central Line IV is blocked, access is done by withdraw 2-3 ml discard of blood, flush with 20 mls.
* If a line is blocked, do not force, the order must be obtained for Cathflo and administered by a certified Cathflo nurse.
* A CHG-Lock™ device will be applied with every intravenous flush for patients in the Active (CHG-LockTM ) arm.
* Bedside nurses will be educated on the use of the CHG-Lock™ device.
* The device will be used for every central line and peripheral IV instillation.
* All locking solutions must be removed prior to access. This is standard of practice.
* Bedside nurses will be asked to document application of the device and instillation in the medication profile.
* Pre-printed Physician Order Set will be created to ensure compliance with device use and protocol.
* A box with devices will be placed at the bedside to ensure ease of access for nurses and that patients receive the device at every lock episode.

Duration of intervention:

* The intervention will be used while the central line or peripheral IV remains in situ.
* The intervention will be discontinued when the patient leaves the ICU or the IV is discontinued.

Measures to be taken to ensure compliance:

1. Study boxes labeled with patient name and ID at the bedside.
2. Staff education (see 3.13)
3. Daily oversight by research coordinator/Assistant

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infection Heart; Surgery, Heart, Functional Disturbance as Result Bacteremia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

An Open Label Randomized Feasibility Pilot Study

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Antiseptic device

Patients who are randomized to receive the device will receive Chlorhexidine at a dose of 0.24-0.42 mg/installation into all intravenous lines. The intervention will be administered every 24 hrs and as needed for as long as the intravenous is in place

Group Type EXPERIMENTAL

Chlorhexidine flush

Intervention Type DEVICE

1. For patients randomized to the CHG-LockTM device, attach a attach a BD Posiflush ™ 0.9% Sodium Chloride (Na Cl) 10ml syringe and a CHG-Lock™ device for each IV line that is to be locked. Follow hospital approved protocol for flush, volumes and hand hygiene.

After a Catheter has been locked, before re-accessing the catheter for further sampling or infusions, all fluid should be aspirated from the catheter to clear the device of CHG, Heparin and the like. This should also confirm patency of the device.
2. Discard the syringe and device in biohazard waste.
3. "Blue Cap" the IV as per routine practice.

Routine Care

Patients who are randomized to routine care (no device, no intervention) will receive normal saline flush as per standard ICU care.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chlorhexidine flush

1. For patients randomized to the CHG-LockTM device, attach a attach a BD Posiflush ™ 0.9% Sodium Chloride (Na Cl) 10ml syringe and a CHG-Lock™ device for each IV line that is to be locked. Follow hospital approved protocol for flush, volumes and hand hygiene.

After a Catheter has been locked, before re-accessing the catheter for further sampling or infusions, all fluid should be aspirated from the catheter to clear the device of CHG, Heparin and the like. This should also confirm patency of the device.
2. Discard the syringe and device in biohazard waste.
3. "Blue Cap" the IV as per routine practice.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CHG-Lock™

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18-100 year old adult patients admitted to the ICU;
2. Same-day admit to ICU;
3. Post-op patient with central lines in situ (PICC, multi-lumen, side arm of introducer catheters or temporary dialysis lines), AND;
4. Expected to have at least 1 central line in situ for more than 72 hrs.

Exclusion Criteria

1. \>24hrs post-admittance to ICU
2. Hopeless prognosis
3. Currently admitted with known infection or suspicion of infection (i.e. known endocarditis or other infections).
4. Chronic indwelling central venous catheters present
5. Patients with known allergies to chlorhexidine

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No